Efficacy and safety of time-of-day infusion of pemetrexed plus platinum for patients with advanced non-small cell lung cancer: a retrospective cohort study

Feb 9, 2026Journal of thoracic disease

Effectiveness and safety of giving pemetrexed plus platinum chemotherapy at different times of day for advanced lung cancer patients

AI simplified

Abstract

The morning chemotherapy group experienced a progression-free survival (PFS) of 24.0 months compared to 14.0 months for the afternoon group (P=0.04).

  • Morning administration of pemetrexed plus platinum chemotherapy is associated with significantly longer progression-free survival in advanced non-small cell lung cancer (NSCLC) compared to afternoon administration.
  • Subgroup analysis indicates that the morning group consistently showed better PFS across all major patient subgroups.
  • The rates of treatment-emergent adverse events were similar between morning and afternoon groups, suggesting comparable safety profiles.
  • However, a higher incidence of grade ≥3 treatment-emergent adverse events was observed in the morning group compared to the afternoon group.
  • Infusion timing of chemotherapy is identified as an independent prognostic factor for patient outcomes in advanced NSCLC.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free